Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease
|ClinicalTrials.gov Identifier: NCT01647412|
Recruitment Status : Withdrawn (PI left the institution)
First Posted : July 23, 2012
Last Update Posted : April 13, 2015
Of the estimated one million Americans with inflammatory bowel disease (IBD), approximately 20-30% develop this condition during childhood or adolescence, most of whom have Crohn's disease (CD). It appears that some individuals are genetically susceptible to certain nutrients, causing inflammation and disturbance of their immune system, as well as disruption of the intestinal barrier. This leads to malnutrition and inhibited growth, with many patients experiencing intense abdominal pain and diarrhea.
Most physicians treat the disease with drugs that suppress the immune system and decrease the inflammatory process. Although these drugs frequently induce remission, most patients experience a subsequent return of symptoms and fail to catch up on their growth. Additionally, serious side effects are associated with these drugs.
Individuals genetically prone to CD are believed to have a leaky gut that allows substances to pass through the intestinal wall and react with the underlying immune system. Furthermore, those nutrients that are toxic to these individuals pass through the decreased intestinal barrier triggering an extreme immune response. Nutrients that have been implicated include grains, except rice, dairy products, and any food containing carrageenan. Excluding these nutrients from the diet has been shown to beneficial for CD patients. Certain nutraceuticals, such as curcumin and omega-3 fatty acids, have been shown to provide anti-inflammatory effects in IBD patients. In addition, the administration growth hormone (GH), has been shown to alleviate symptoms, by enhancing the repair of the intestinal epithelium, preventing toxic antigens from reaching the underlying lamina propria.
Previous studies and case reports provide incomplete evidence that exclusion diet with nutraceuticals (DNT) and GH lead to sustained long term remission in juvenile CD, discontinuation of other CD drugs, and catch up growth. This study is designed to test this hypothesis. Patients in the treatment group will be treated with DNT and GH, while continuing to receive medications from their physician while the control group will receive DNT, placebo injections instead of GH. We predict that the treatment group will show greater improvement than the control group.
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease||Drug: Growth Hormone Dietary Supplement: Nutraceutical Combination Other: Exclusion Diet Other: Placebo Growth Hormone||Phase 2|
The most widely held hypothesis regarding the pathogenesis of inflammatory bowel disease (IBD) is that overly aggressive acquired immune responses to a subset of commensal enteric bacteria develop in genetically susceptible hosts. In an attempt to avoid disease progression, patients are treated with anti-inflammatory, immunomodulatory and monoclonal antibody drugs, which frequently produce remissions. However, these drugs usually fail to achieve long-term, sustained remission or reversal of growth failure, and are associated with serious side effects. Recently, intestinal barrier dysfunction has been implicated in an alternative 3-step model of IBD pathogenesis.
The investigators hypothesize that the exclusion diet and nutraceutical therapy (DNT) will decrease the production of toxic antigens in the gut and that reactive human growth hormone (rhGH) will reduce the passage of the remaining toxic antigens to the underlying mucosal immune system by promoting the maintenance of the intestinal barrier and accelerating the restitution of the intestinal epithelial lining.
The following study will test whether the the 3-step model is accurate, and whether rhGH and DNT will induce sustained remission in juvenile CD patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Growth Hormone and Nutrition Therapy in Juvenile Crohn's Disease, a Randomized Clinical Trial|
|Study Start Date :||March 2012|
Active Comparator: Growth Hormone, Exclusion Diet, and Nutraceutical therapy
The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
Drug: Growth Hormone
Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.Dietary Supplement: Nutraceutical Combination
Other Names:Other: Exclusion Diet
Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
Placebo Comparator: rhGH placebo, Exclusion diet, and nutraceutical therapy
The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
Dietary Supplement: Nutraceutical Combination
Other Names:Other: Exclusion Diet
Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.Other: Placebo Growth Hormone
- Proportion of Patients in remission [ Time Frame: 26 weeks and 52 weeks ]The proportion of patients in remission in each group will be assessed and compared to each other in order to demonstrate efficacy of treatment. Remission will be assessed by a change in the patients PCDAI score to below 10.
- Bone Mineral Density (BMD) [ Time Frame: Baseline and 52 weeks ]BMD of the hip and spine will be obtained by dual-emission x-ray absorptiometry (DXA) at the baseline visit and week 52.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647412
|United States, New York|
|Columbia University Department of Clinical Genetics|
|New York, New York, United States, 10032|
|Principal Investigator:||Alfred E Slonim, MD||Columbia University|